Preeclampsia is a pregnancy disorder that is associated with negative outcomes for both mother and baby. It is a precursor to eclampsia, which causes seizures (Garg et al., 2015), and is associated with high blood pressure and large amounts of protein in the urine (Ghulmiyyah & Sibai, 2012). Rates of preeclampsia are higher in patients who are older and those with a history of obesity, hypertension, and diabetes mellitus (Li et al., 2014). Preeclampsia affects 2-8% of pregnancies (Li et al., 2014), and caused 29,000 deaths in 2013 (Garg et al., 2015). As such, it is necessary to understand interventions to reduce the risk of preeclampsia.
To assess whether the supplementation of aspirin in at-risk groups reduces the incidence of preeclampsia
To assess whether the supplementation of aspirin in individuals with preeclampsia reduces the incidence of negative outcomes
A quantitative study is proposed here. There will be three study groups involved in this study. The first will be a control group who will follow normal recommended protocol. The second group will be those women who are pregnant, had a BMI higher than 30 prior to pregnancy or who are older than 35. These participants will take low-dose aspirin from 12 weeks into their pregnancy. The final group will be those who are showing signs of preeclampsia in their pregnancy. These participants will take low-dose aspirin from the first sign of preeclampsia.
This study is significant because preeclampsia is one of the most common but least understood disorders of pregnancy (Roberge et al., 2012). It causes a significant amount of complications for both the woman and her child and it can be fatal for either or both (Lisonkova & Joseph, 2013). As such, reducing the rates of preeclampsia and the risks of death from the complication is important for improving outcomes from pregnancy.